NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) completed the safety analysis from its Phase 2 study of PrimeC in Alzheimer's disease, reporting ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE